文献速递前列腺增生与排尿功能障碍

减少液体摄入能否解释膀胱过度活动症临床试验中观察到的安慰剂效应?大型索利那新整合数据库分析

Could Reduced Fluid Intake Cause the Placebo Effect Seen in Overactive Bladder Clinical Trials? Analysis of a Large Solifenacin Integrated Database.
PubMed 文献 · Urology · 2017-04-20

该分析基于4项随机安慰剂对照III期索利那新膀胱过度活动症研究整合的3011例患者数据,采用统计校正去除液体摄入对排尿频率的影响。结果显示安慰剂组24小时总尿量较基线明显下降而索利那新组不明显,校正排尿量后排尿频率的安慰剂效应几乎消失;作者假设排尿量可反映液体摄入,认为液体限制几乎完全解释了安慰剂组的排尿频率下降。

要点

  • 安慰剂组从基线至第4周24小时尿量明显下降,索利那新组无此现象。
  • 对每例患者排尿频率按排尿量统计校正后,安慰剂效应几乎消失。
  • 索利那新组排尿次数更少,且每次排尿量较安慰剂组有统计学显著增加。

核心结论

  • 假设排尿量是液体摄入的良好替代指标,本分析显示液体限制几乎完全解释了安慰剂组排尿频率的下降。
  • 接受活性治疗的患者在开始感知膀胱过度活动症症状改善后采取更正常的饮水模式。

研究设计与样本

  • 对包含4项随机、安慰剂对照III期索利那新膀胱过度活动症研究患者数据的整合数据库进行汇总分析,共3011例患者。
  • 对排尿频率施加统计校正以去除液体摄入的影响,并在模型中考虑研究间差异。

主要发现

  • 所有患者在治疗期间每24小时排出的总尿量均较基线逐渐减少。
  • 每24小时排出总尿量的减少在安慰剂组大于索利那新组;安慰剂组24小时尿量从基线至第4周明显下降,而活性治疗组未出现这种情况。
  • 对每例患者排尿频率按排尿量进行统计校正并按治疗组平均后,安慰剂效应几乎消失。
  • 索利那新组排尿次数更少,且每次排尿量较安慰剂组有统计学显著增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the hypothesis that patients receiving placebo in overactive bladder (OAB) trials who experience less benefit from "treatment" continue with behavioral modifications such as fluid restriction, whereas those on active treatment adopt more normal drinking patterns. This may manifest itself as a reduction in micturition frequency (MF). MATERIALS AND METHODS: We interrogated a large integrated database containing pooled patient data from 4 randomized, placebo-controlled phase III OAB solifenacin studies. A statistical correction was applied to MF to remove the influence of fluid intake. RESULTS: Pooled analysis using patient-level data from 3011 patients and accounting for the studies within the models showed that all patients voided progressively less total urine per 24 hours during treatment than at baseline. However, reduction in total urine volume voided per 24 hours was larger in patients receiving placebo vs those on solifenacin; with a substantial decrease in 24-hour urine output in the placebo group from baseline to week 4, which was not the case in active groups. After correcting MF for volume voided for each patient using the statistical correction and averaging the corrected MF per treatment arm, the placebo effect almost disappeared. Patients on solifenacin voided less often, with a statistically significant increase in volume voided each time they voided, vs placebo. CONCLUSION: Assuming volume voided is a good surrogate measure for fluid intake, this analysis shows that fluid restriction almost completely explains the reduction in MF in the placebo group. In contrast, patients receiving active treatment adopt more normal drinking patterns once they start to perceive improvement in their OAB symptoms.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Herschorn S, Chapple CR, Snijder R, et al. Could Reduced Fluid Intake Cause the Placebo Effect Seen in Overactive Bladder Clinical Trials? Analysis of a Large Solifenacin Integrated Database. Urology. 2017. PMID: 28435033. doi:10.1016/j.urology.2017.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。